Epilepsy and COVID-19: patient management and optimization of antiepileptic therapy during pandemic

This article was originally published here

Zh Nevrol Psikhiatr Im S S Korsakova. 2020;120(10):100-107. doi: 10.17116/jnevro2020120101100.


There is currently no data on the increased incidence of new coronavirus infection (COVID-19) or on the more severe course of the disease in patients with epilepsy. However, given the high prevalence of epilepsy among patients after age 60, an increased burden of somatic comorbidities among people with epilepsy, as well as the need of continuous access to antiepileptic drugs (AED) and care for patients with epilepsy, there are a number of important concerns in time of regarding the management of epilepsy during COVID-19 pandemic. The article discusses the main principles of epilepsy management during the COVID-19 pandemic: the need to comply with the regime; the importance of AED adherence, taking into account drug-drug interactions; switching patients to intravenous AED forms if necessary.

PMID:33244965 | DOI:10.17116/jnevro2020120101100